A total of 36 of the 58 participants had FLT3-mutated AML, and those who had FLT-mutated AML achieved a composite complete response of 89%; however, there were concerns about delayed count recovery, and a longer count recovery time was associated with a high gilteritinib trough concentration [30]. Here, FLT3 is linked to acute myeloid leukemia.